Q32 Bio Inc. (QTTB) stock analysis
Close on Nov 13, 2026Market cap $259.29MP/E –Yield –
StockData Score
Prices as of Nov 13, 2026How the score works
Mixed11 of 30 checks passed
Q32 Bio passes 11 of the 30 checks behind our score; 18 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 3/6
- Growth
- 1/6
- Past performance
- 1/6
- Financial health
- 6/6
- Dividend
- 0/6
What stands out
Margin of safety over 20%
The price is 57.1% below fair value, more than the 20% cushion we look for.
Trading below fair value
The share price of $8.71 is below our fair value estimate of $20.33.
No debt
Q32 Bio has no borrowings on its latest balance sheet.
Revenue growing 10%+ a year
Revenue grew 156% a year over the last three fiscal years.
What to watch
No dividend
Q32 Bio has not paid a dividend in the last twelve months.
Valuation3/6
P/E against its history
Not enough price and earnings history to compare.
P/E against the industry
Needs positive earnings and enough profitable companies in the industry.
EV/EBITDA against its history
Needs positive EBITDA and price history.
P/B below the industry
Q32 Bio's price-to-book of 0.90 is below the Drugs median of 2.09.
Trading below fair value
The share price of $8.71 is below our fair value estimate of $20.33.
Margin of safety over 20%
The price is 57.1% below fair value, more than the 20% cushion we look for.
Growth1/6
Revenue growing 10%+ a year
Revenue grew 156% a year over the last three fiscal years.
EPS growth over 3 years
Needs positive EPS three years ago and today.
Earnings acceleration
Needs positive net income now, a year ago and five years ago.
Growth against the industry
Needs revenue for this year and last.
Company guidance
No outlook found in earnings releases from the last twelve months.
Gross margin trend
This company does not report gross profit.
Past performance1/6
Return on equity
Needs positive equity and five years of results.
Return on invested capital
Needs operating income and invested capital.
Return on equity above the industry
Q32 Bio's return on equity of 24.0% is above the Drugs median of -57.0%.
Earnings over 5 years
Needs positive net income five years ago and in the latest year.
Net margin against its history
Needs five years of revenue and net income.
Net margin against the industry
Needs revenue and net income.
Financial health6/6
No debt
Q32 Bio has no borrowings on its latest balance sheet.
Debt not rising
With no debt today, leverage cannot have risen.
Debt covered by cash flow
There is no debt to cover.
Interest well covered
No meaningful interest expense to cover.
Short-term assets cover short-term debts
Current assets are 56.34 times current liabilities.
Low bankruptcy risk
The Altman Z-score is 16.60; above 3 is the safe zone and below 1.8 the distress zone.
Dividend0/6
No dividend
Q32 Bio has not paid a dividend in the last twelve months.
Yield against Treasuries
No dividend.
Yield against the market
No dividend.
Dividend stability
No dividend.
Earnings cover
No dividend.
Cash-flow cover
No dividend.
Fair value
How we estimate itOur estimate per share
$20.33
The share price is 57% below this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| EV/EBITDA | 17.4× | – | 17.4× | $20.49 | 78% |
| P/B | 2.0× | 1.9× | 2.1× | $19.76 | 22% |
| Fair value | $20.33 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/B at month end
- Own 5-year median 1.9
- Drugs median 2.1
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Medium risk
- Average value traded per day
- $4.22M
- Value traded per 1% price move
- $1.80M
Downside
High risk
- Typical loss in a bad month
- 38.7%
- Volatility (annualized)
- 170%
- Sharpe ratio, 1 year
- 1.49
- Beta to the S&P 500 (5Y)
- 0.67
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | +155.9% | +81.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -56.6% | 125.1% | |
| Return on assets | – | -44.8% | 38.7% | |
| Current ratio | – | 9.69 | 4.85 | |
| Capex to revenue | – | 138.2% | 0.0% | |
| Diluted shares | – | 0M | 12M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Q32 Bio generated $343.35M from operations and spent $3.76M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 55.5% | 0.70× | 3.23× | 125.1% |
| FY2023 | 808.0% | -0.05× | -0.88× | 34.3% |
| FY2022 | -156.0% | 0.01× | 11.30× | -25.7% |
| FY2021 | -281.9% | 0.14× | 1.30× | -52.4% |
| FY2020 | -4762.9% | 0.01× | 1.26× | -56.6% |
| FY2019 | -6237.5% | 0.01× | 1.25× | -45.7% |
| FY2018 | -1044.3% | 0.03× | 2.53× | -70.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$29.82M
- Cash generatingOperating cash flow above zero-$33.54M
- Return on assets improvedROA up on the prior year-101.4% → 32.3%
- Earnings backed by cashOperating cash flow above net income-$33.54M vs $29.82M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.97 → 4.85
- No dilutionShare count did not rise10M → 12M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.58
See a number that looks wrong?